ITIL-306 is a gene-modified cell therapy commercialized by Instil Bio, with a leading Phase I program in Squamous Non-Small Cell Lung Carcinoma. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of ITIL-306’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for ITIL-306 is expected to reach an annual total of $43 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

ITIL-306 Overview

ITIL-306 is under development for the treatment of gynecological cancers, non-small cell lung cancer, epithelial ovarian cancer, renal cell carcinoma (RCC), high grade serous, endometrioid, or clear cell epithelial carcinoma of fallopian tube, or peritoneum and solid tumors. The therapeutic candidate comprises tumor infiltrating lymphocytes (TIL) genetically engineered to express a Co-Stimulatory Antigen Receptor (CoStAR) molecule targeting folate receptor alpha (FOLR1). It is administered through parenteral route.

Instil Bio Overview

Instil Bio is a biopharmaceutical company that develops optimized and genetically-engineered tumor infiltrating lymphocytes (TIL) for the treatment of cancer. It is investigating its lead product candidate ITIL-168 against melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer. The company is also evaluating ITIL-306 drug to treat gynaecological malignancies and other tumors. Instil Bio utilizes its proprietary TIL manufacturing platform to develop its products. The company operates research and cell therapy manufacturing facilities in Los Angeles, the US; and Manchester, the UK. Instil Bio is headquartered in Dallas, Texas, the US.

The operating loss of the company was US$155.6 million in FY2021, compared to an operating loss of US$33.6 million in FY2020. The net loss of the company was US$156.8 million in FY2021, compared to a net loss of US$37.7 million in FY2020.

For a complete picture of ITIL-306’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.